Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
By C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M. R. Rutten-van Mölken, K. Beeh, K. Rabe, L. Fabbri. New England Journal of Medicine, 2011
716 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/a344225ac7452161585613a1eda2613db9869536
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017, background): “Group D patients are at higher risk for pneumonia when receiving ICS treatment.(111,135)”
- Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, neutral): “В другом крупном клиническом исследова нии было отмечено, что тиотропий несколько более эф фективен в уменьшении частоты обострений, чем сал метерол, хотя различие незначительно [215, 517].”
- Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society (2011, neutral): “Adverse effects were similar between groups (39).”